跳至主要内容
临床试验/CTRI/2021/11/037753
CTRI/2021/11/037753招募中4 期

A 24 week randomized controlled trial assessing the effect of Glimepiride/ Metformin/ Vildagliptin/ Dapagliflozin on glycemic control in novel subtypes - Trial phase IV. - CLUSTER

SV Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. New onset of Type 2 diabetes (within 2 years of diagnosis)
  • 2. Drug naive
  • 3. Body Mass Index (BMI) ââ?°Â¤ 40.0 kg/m2
  • 4. HbA1c (Glycated Hemoglobin) ââ?°Â¥ 7.0%

排除标准

  • 1. Type 1 Diabetes
  • 2. Use of any oral hypoglycemic agents or Insulin in past
  • 3. Patients with a serum creatinine concentration greater than 132.6 mmol/L or liver function impairment
  • 4. Significant alcohol, drug, or medication abuse
  • 5. Currently under psychiatric care or using antipsychotic or mood stabilizer medication or diagnosed to have dementia or bipolar disorder or schizophrenia
  • 6. History of anemia or hemoglobinopathy and/ or hemoglobin < 10 g/dL for men , <9 g/dL for women
  • 7. Pregnant or lactating women
  • 8. Documented CVD event in past 12 months

研究者

发起方
SV Private Limited

相似试验